Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Journal of experimental & clinical cancer research : CR - 15 Feb 2018

Blandino Giovanni, Di Agostino Silvia

Abstract excerpt

The tumor suppressor p53 plays a critical role to preserve DNA fidelity from diverse insults through the regulation of cell-cycle checkpoints, DNA repair, senescence and apoptosis. The TP53 is the most frequently inactivated gene in human cancers. This leads to the production of mutant p53 proteins that loose wild-type p53 tumor suppression functions and concomitantly acquire new oncogenic properties among which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Treatment Outcome
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Gene Expression Regulation, Neoplastic

Share to Genomic Instability

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 29448954
DOI: 10.1186/s13046-018-0705-7
PMCID: PMC5815234

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New therapeutic strategies to treat human cancers expressing mutant p53 proteins.PMID 29448954Read ↗

Targeting Oncogenic Mutant p53 for Cancer TherapySemantic proximity Read ↗

Molecularly targeted therapies for p53-mutant cancers.Semantic proximity Read ↗

Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies.Semantic proximity Read ↗

Mutant p53 in Cancer Progression and Targeted TherapiesSemantic proximity Read ↗

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and OpportunitiesSemantic proximity Read ↗

Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.Semantic proximity Read ↗

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.Semantic proximity Read ↗

The Development of p53-Targeted Therapies for Human CancersSemantic proximity Read ↗

Strategies for manipulating the p53 pathway in the treatment of human cancer.Semantic proximity Read ↗

p53 signaling in cancer progression and therapySemantic proximity Read ↗

Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?Semantic proximity Read ↗

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perilsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.